LLY vs OPK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
OPK exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in profitability and operational efficiency. While the company maintains a strong liquidity position with a current ratio of 3.97 and low debt, these are offset by a -19.2% decline in year-over-year revenue and deeply negative profit margins. The stock is trading below its book value (P/B 0.71), but the persistent long-term price decay (-72.8% over 5 years) suggests a value trap rather than a bargain. Despite optimistic analyst price targets, the deterministic data points to a company in structural decline.
Compare Another Pair
Related Comparisons
LLY vs OPK: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and OPKO Health, Inc. (OPK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.